New Zealand markets closed

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
42.74+0.70 (+1.67%)
At close: 04:00PM EDT
42.87 +0.13 (+0.30%)
After hours: 05:12PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 18.72B
Enterprise value 22.91B
Trailing P/E 29.95
Forward P/E 14.53
PEG ratio (5-yr expected) N/A
Price/sales (ttm)8.00
Price/book (mrq)3.23
Enterprise value/revenue 10.05
Enterprise value/EBITDA 16.26

Trading information

Stock price history

Beta (5Y monthly) 0.37
52-week change 32.79%
S&P500 52-week change 3-11.93%
52-week high 344.75
52-week low 334.86
50-day moving average 340.81
200-day moving average 339.56

Share statistics

Avg vol (3-month) 32.44M
Avg vol (10-day) 33M
Shares outstanding 5435.32M
Implied shares outstanding 6N/A
Float 8340.96M
% held by insiders 115.48%
% held by institutions 163.15%
Shares short (14 Jun 2022) 413.73M
Short ratio (14 Jun 2022) 47.34
Short % of float (14 Jun 2022) 44.43%
Short % of shares outstanding (14 Jun 2022) 43.15%
Shares short (prior month 12 May 2022) 48.35M

Dividends & splits

Forward annual dividend rate 40.76
Forward annual dividend yield 41.78%
Trailing annual dividend rate 30.70
Trailing annual dividend yield 31.67%
5-year average dividend yield 4N/A
Payout ratio 448.95%
Dividend date 314 Jun 2022
Ex-dividend date 418 May 2022
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 26.44%
Operating margin (ttm)62.37%

Management effectiveness

Return on assets (ttm)5.34%
Return on equity (ttm)12.12%

Income statement

Revenue (ttm)2.28B
Revenue per share (ttm)5.35
Quarterly revenue growth (yoy)-1.90%
Gross profit (ttm)1.84B
Net income avi to common (ttm)602.37M
Diluted EPS (ttm)1.43
Quarterly earnings growth (yoy)-25.10%

Balance sheet

Total cash (mrq)2.34B
Total cash per share (mrq)5.38
Total debt (mrq)7.1B
Total debt/equity (mrq)70.02
Current ratio (mrq)21.95
Book value per share (mrq)13.27

Cash flow statement

Operating cash flow (ttm)1.95B
Levered free cash flow (ttm)-1.06B